Immunogenicity and safety of a new hexavalent rotavirus vaccine in Chinese infants: A randomized, double-blind, placebo-controlled phase 2 clinical trial

References

• Kuri PR, Goswami P. Current update on rotavirus in-silico multiepitope vaccine design. ACS Omega. 2023;8(1):190–7. doi:10.1021/acsomega.2c07213.
   PubMed Web of Science ®Google Scholar
• Britoh Mlan A, Burke RM, Koné H, Boni-Cisse C, N’Guessan R, Zaba F, Aka LN, N’Zue K, Adom SK, Kouadio SK, et al. Impact of rotavirus vaccine introduction in Abidjan, Côte d’Ivoire. Hum Vaccin Immunother. 2023;19(1):2156231. doi:10.1080/21645515.2022.2156231.
   PubMed Web of Science ®Google Scholar
• Gundogdu Z, Yendur Sezer O. Changing parental attitudes towards rotavirus vaccine. Cureus. 2023;15:e35348. doi:10.7759/cureus.35348.
   PubMed Web of Science ®Google Scholar
• Ndwandwe D, Runeyi S, Mathebula L, Wiysonge C. Rotavirus vaccine clinical trials: a cross-sectional analysis of clinical trials registries. Trials. 2022;23(1):945. doi:10.1186/s13063-022-06878-6.
   PubMed Web of Science ®Google Scholar
• Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:136–41. doi:10.1016/S1473-3099(11)70253-5.
   PubMed Web of Science ®Google Scholar
• Soares-Weiser K, Bergman H, Henschke N, Pitan F, Cunliffe N. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2019. doi:10.1002/14651858.CD008521.pub5.
   Web of Science ®Google Scholar
• Bergman H, Henschke N, Hungerford D, Pitan F, Ndwandwe D, Cunliffe N, Soares-Weiser K. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2021;11:Cd008521. doi:10.1002/14651858.CD008521.pub6.
   PubMedGoogle Scholar
• Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1459–544. doi:10.1016/S0140-6736(16)31012-1.
   PubMed Web of Science ®Google Scholar
• Troeger C, Khalil IA, Rao PC, Cao S, Blacker BF, Ahmed T, Armah G, Bines JE, Brewer TG, Colombara DV, et al. Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. JAMA Pediatr. 2018;172(10):958–65. doi:10.1001/jamapediatrics.2018.1960.
   PubMed Web of Science ®Google Scholar
• Buchy P, Chen J, Zhang XH, Benninghoff B, Lee C, Bibera GL. A review of rotavirus vaccine use in Asia and the Pacific regions: challenges and future prospects. Expert Rev Vaccines. 2021;2021:1–16. doi:10.1080/14760584.2020.1853532.
   Google Scholar
• Rodriguez WJ, Kim HW, Brandt CD, Schwartz RH, Gardner MK, Jeffries B, Parrott RH, Ksalow RA, Smith JI, Kapikian AZ, et al. Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: clinical and epidemiologic observations. Pediatr Infect Dis J. 1987;6(2):170–6. doi:10.1097/00006454-198702000-00006.
   PubMed Web of Science ®Google Scholar
• Kanungo S, Chatterjee P, Bavdekar A, Murhekar M, Babji S, Garg R, Samanta S, Nandy RK, Kawade A, Boopathi K, et al. Safety and immunogenicity of the rotavac and rotasiil rotavirus vaccines administered in an interchangeable dosing schedule among healthy Indian infants: a multicentre, open-label, randomised, controlled, phase 4, non-inferiority trial. Lancet Infect Dis. 2022;22(8):1191–9. doi:10.1016/S1473-3099(22)00161-X.
   PubMed Web of Science ®Google Scholar
• Wu Z, Li Q, Liu Y, Lv H, Mo Z, Li F, Yu Q, Jin F, Chen W, Zhang Y, et al. Efficacy, safety and immunogenicity of hexavalent rotavirus vaccine in Chinese infants. Virol Sin. 2022;37(5):724–30. doi:10.1016/j.virs.2022.07.011.
   PubMed Web of Science ®Google Scholar
• Wu ZW, Li QL, Zhou HS, Duan K, Gao Z, Zhang XJ, Jiang ZJ, Hao ZY, Jin F, Bai X, et al. Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine: a phase I clinical trial. Hum Vaccines Immunother. 2021;17:2311–8. doi:10.1080/21645515.2020.1861874.
   PubMed Web of Science ®Google Scholar
• China National Medical Products Administration. Guidelines for grading standards of adverse events in clinical trials of preventive vaccines. 2019 [accessed 2020 Nov 3]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20191231111901460.html.
   Google Scholar
• Ravish HS, Sudarshan MK, Madhusudana SN, Annadani RR, Narayana DH, Belludi AY, Anandaiah, G., Vijayashankar, V. Assessing safety and immunogenicity of post-exposure prophylaxis following interchangeability of rabies vaccines in humans. Hum Vaccines Immunother. 2014;10:1354–8. doi:10.4161/hv.28064.
   PubMed Web of Science ®Google Scholar
• Groome MJ, Koen A, Fix A, Page N, Jose L, Madhi SA, McNeal M, Dally L, Cho I, Power M, et al. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2017;17(8):843–53. doi:10.1016/S1473-3099(17)30242-6.
   PubMed Web of Science ®Google Scholar
• Chilengi R, Mwila-Kazimbaya K, Chirwa M, Sukwa N, Chipeta C, Velu RM, Katanekwa N, Babji S, Kang G, McNeal MM, et al. Immunogenicity and safety of two monovalent rotavirus vaccines, ROTAVAC(R) and ROTAVAC 5D(R) in Zambian infants. Vaccine. 2021;39:3633–40. doi:10.1016/j.vaccine.2021.04.060.
   PubMed Web of Science ®Google Scholar
• Coldiron ME, Guindo O, Makarimi R, Soumana I, Matar Seck A, Garba S, Macher E, Isanaka S, Grais RF. Safety of a heat-stable rotavirus vaccine among children in Niger: data from a phase 3, randomized, double-blind, placebo-controlled trial. Vaccine. 2018;36:3674–80. doi:10.1016/j.vaccine.2018.05.023.
   PubMed Web of Science ®Google Scholar
• Cohet C, Cheuvart B, Moerman L, Bi D, Caplanusi A, Kariyappa M, Lalwani S, Mitra M, Sapru A, Saha S, et al. A phase III randomized, open-label, non-inferiority clinical trial comparing liquid and lyophilized formulations of oral live attenuated human rotavirus vaccine (HRV) in Indian infants. Hum Vaccines Immunother. 2021;17(11):4646–53. doi:10.1080/21645515.2021.1960136.
   PubMed Web of Science ®Google Scholar
• Kanchan V, Zaman K, Aziz AB, Zaman SF, Zaman F, Haque W, Khanam M, Karim MM, Kale S, Ali SK, et al. A randomized phase I/II study to evaluate safety and reactogenicity of a heat-stable rotavirus vaccine in healthy adults followed by evaluation of the safety, reactogenicity, and immunogenicity in infants. Hum Vaccines Immunother. 2020;16(3):693–702. doi:10.1080/21645515.2019.1664239.
   PubMed Web of Science ®Google Scholar
• Witte D, Handley A, Jere KC, Bogandovic-Sakran N, Mpakiza A, Turner A, Pavlic D, Boniface K, Mandolo J, Ong DS, et al. Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study. Lancet Infect Dis. 2022;22(5):668–78. doi:10.1016/S1473-3099(21)00473-4.
   PubMed Web of Science ®Google Scholar
• Bines JE, Danchin M, Jackson P, Handley A, Watts E, Lee KJ, West A, Cowley D, Chen M-Y, Barnes GL, et al. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2015;15(12):1389–97. doi:10.1016/S1473-3099(15)00227-3.
   PubMed Web of Science ®Google Scholar
• Bines JE, At Thobari J, Satria CD, Handley A, Watts E, Cowley D, Nirwati H, Ackland J, Standish J, Justice F, et al. Human neonatal rotavirus vaccine (RV3-BB) to target rotavirus from birth. New Engl J Med. 2018;378(8):719–30. doi:10.1056/NEJMoa1706804.
   PubMed Web of Science ®Google Scholar
• At Thobari J, Damayanti W, Haposan JH, Nirwati H, Iskandar K, Samad, Fahmi J, Sari RM, Bachtiar NS, Watts E, et al. Safety and immunogenicity of human neonatal RV3 rotavirus vaccine (bio farma) in adults, children, and neonates in Indonesia: phase I trial. Vaccine. 2021;39:4651–8. doi:10.1016/j.vaccine.2021.06.071.
   PubMed Web of Science ®Google Scholar
• Angel J, Franco MA, Greenberg HB. Rotavirus immune responses and correlates of protection. Curr Opin Virol. 2012;2(4):419–25. doi:10.1016/j.coviro.2012.05.003.
   PubMed Web of Science ®Google Scholar
• Offit PA. Correlates of protection against rotavirus infection and disease. Novartis Found Symp. 2001;238:106–13. discussion 14-24.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Recent updates on correlates of vaccine-induced protection. Front Immunol. 2022;13:1081107. doi:10.3389/fimmu.2022.1081107.
   PubMed Web of Science ®Google Scholar
• Pollock L, Bennett A, Jere KC, Mandolo J, Dube Q, Bar-Zeev N, Heyderman RS, Cunliffe NA, Iturriza-Gomara M. Plasma rotavirus-specific IgA and risk of rotavirus vaccine failure in infants in Malawi. Clin Infect Dis. 2022;75:41–6. doi:10.1093/cid/ciab895.
   PubMed Web of Science ®Google Scholar
• Holmgren J, Parashar UD, Plotkin S, Louis J, Ng SP, Desauziers E, Picot V, Saadatian-Elahi M. Correlates of protection for enteric vaccines. Vaccine. 2017;35:3355–63. doi:10.1016/j.vaccine.2017.05.005.
   PubMed Web of Science ®Google Scholar
• Clarke E, Desselberger U. Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings. Mucosal Immunol. 2015;8(1):1–17. doi:10.1038/mi.2014.114.
   PubMed Web of Science ®Google Scholar
• Mo Z, Ma X, Luo P, Mo Y, Kaplan SS, Shou Q, Zheng M, Hille DA, Arnold BA, Liao X, et al. Immunogenicity of pentavalent rotavirus vaccine in Chinese infants. Vaccine. 2019;37(13):1836–43. doi:10.1016/j.vaccine.2019.02.018.
   PubMed Web of Science ®Google Scholar
• Li RC, Li YP, Mo ZJ, Luo D, Huang T, Kong JL, Wang L-H, Song N-S, Liu A, Zhang H, et al. Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled phase I studies. Hum Vaccines Immunother. 2013;9(8):1638–42. doi:10.4161/hv.25076.
   PubMed Web of Science ®Google Scholar
• Li RC, Huang T, Li Y, Wang LH, Tao J, Fu B, Si G, Nong Y, Mo Z, Liao X, et al. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants. Hum Vaccines Immunother. 2016;12(3):785–93. doi:10.1080/21645515.2015.1085143.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New Engl J Med. 2006;354:23–33. doi:10.1056/NEJMoa052664.
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New Engl J Med. 2006;354(1):11–22. doi:10.1056/NEJMoa052434.
   PubMed Web of Science ®Google Scholar